|
|
|
SUO 2025 Preview: Bladder Cancer Data from BCG-Unresponsive to Metastatic Disease
|
|
Patrick Hensley, MD
|
| Sam Chang hosts Patrick Hensley to preview the bladder cancer session at the 2025 SUO meeting, highlighting several clinical trial updates.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Anticipated Data, Discussions, and Expert Perspectives
|
|
|
|
|
Wednesday, December 3, 2025
|
|
| State of the Art Session II: Incorporating Minimal Residual Disease in ctDNA Testing/Assays in Clinical Practice in Bladder Cancer: Are We There Yet? - 1500-1600 MST
|
|
|
|
|
| Posters - 14:00 - 18:00 MST
|
|
|
|
|
ProstACT Global: A Phase 3 Study of Lutetium (Lu177) Rosopatamab Tetraxetan plus SoC vs SoC Alone in Patients with Metastatic Castration-Resistant Prostate Cancer
Presented By: Neeraj Agarwal, MD, FASCO
|
|
|
|
|
Simulating Outcomes of EV302 with Use of Maintenance Avelumab in Control Arm Patients
Presented By: Fady Ghali, MD
|
|
|
|
|
Physician Experiences With TAR-200 in High-Risk Nonmuscle-Invasive Bladder Cancer: A Qualitative Study of SUNRISE Trial Investigators
Presented By: Joshua Meeks, MD, PhD
|
|
|
|
|
Durable 24-Month Outcomes From BOND-003 Cohort C: Phase 3 Study of Intravesical Cretostimogene Grenadenorepvec for High-Risk BCG-Unresponsive Nonmuscle-Invasive Bladder Cancer With Carcinoma in Situ
Presented By: Mark Tyson, II, MD, MPH
|
|
|
|
|
CORE-008 Cohort B: Evaluating Intravesical Cretostimogene Grenadenorepvec in Patients With High-Risk, BCG-Exposed Nonmuscle-Invasive Bladder Cancer
Presented By: Trinity J. Bivalacqua, MD, PhD
|
|
|
|
|
|
Thursday, December 4, 2025
|
|
| Late Breaking Abstract - 08:30 - 08:40 MST
|
|
|
|
|
Phase II Trial of Neoadjuvant Stereotatic Ablative Radiotherapy for Caval Tumor Thrombus in Newly Diagnosed Renal Cell Carcinoma
Presented By: Lin Lin
|
|
|
|
|
Relief of Venous Congestion as a Modifiable Cause of Renal Dysfunction in RCC With IVC Tumor Thrombus: A Comparative Cohort Study
Presented By: Lorraine Scanlon, MD
|
|
|
|
|
| Posters - 08:00 - 17:30 MST
|
|
|
|
|
TRIPLE-SWITCH(SWOG/CCTG-PR26): Randomized Phase III Clinical Trial of Docetaxel with Androgen Receptor Pathway Inhibitors for Metastatic Castration-Sensitive Prostate Cancer Patients with a Suboptimal PSA Response
Presented By: Alexandra Sokolova, MD
Costs of Care and Oncologic Outcomes Associated With Blue Light Cystoscopy in an Equal Access Setting: Results From the BRAVO Study
Presented By: Ali Nasrallah, MD
Sasanlimab in Combination With BCG in BCG-naive, High-Risk Nonmuscle-Invasive Bladder Cancer: Exploratory Analysis Evaluating BCG-Unresponsive Disease
Presented By: Gary D. Steinberg, MD
|
|
|
|
|
|
|
|
|
|
Impact of 89Zr-Girentuximab PET/CT Versus Conventional Imaging on Clinical Decision-making in Patients With Indeterminate Renal Masses (ZIRCON-x)
Presented By: Brian M. Shuch, MD
|
|
|
|
|
IDeate-Prostate01: A Phase 3, Randomized, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants With Previously Treated Metastatic Castration-resistant Prostate Cancer
Presented By: Rana McKay, MD, FASCO
|
|
|
|
|
|
|
| Prostate Cancer Session II - Late Breaking Abstract - 09:00 - 10:00 MST
|
|
|
|
|
PSMAddition: Top Line Results From a Phase 3 Trial of ADT and ARPI +/- [177Lu]Lu-PSMA-617 in Patients With PSMA-Positive Metastatic Hormone-Sensitive Prostate Cancer
Presented By: Scott Tagawa, M.D., MS, FACP, FASCO
|
|
|
|
|
| Bladder Cancer Session II - Late Breaking Abstracts - 02:20 - 02:45 PM MST
|
|
|
|
|
Primary Efficacy and Surgical Details in KEYNOTE-905: Neoadjuvant and Adjuvant Enfortumab Vedotin Plus Pembrolizumab in Participants With Muscle-Invasive Bladder Cancer Who Are Cisplatin-Ineligible
Presented By: Hristos Kaimakliotis, MD
|
|
|
|
|
Circulating Tumor DNA-Guided Adjuvant Atezolizumab vs Placebo in Patients With Muscle-Invasive Bladder Cancer After Radical Cystectomy: Exploratory Subgroup Analysis of the Phase 3 IMvigor011 Trial
Presented By: Jürgen E. Gschwend, MD
|
|
|
|
|
Topline Results From BOND-003 Cohort P, A Multi-National, Single-arm Study of Intravesical Cretostimogene Grenadenorepvec for Treatment of High-Risk, Papillary Only, BCG-Unresponsive Nonmuscle-Invasive Bladder Cancer
Presented By: Mark Tyson, II, MD, MPH
|
|
|
|
|
First Results From CORE-008 Cohort A, A Phase 2 Study of Intravesical Cretostimogene Grenadenorepvec in Patients With High-Risk BCG-Naïve Nonmuscle-Invasive Bladder Cancer
Presented By: Trinity J. Bivalacqua, MD, PhD
|
|
|
|
|
Gemcitabine Intravesical System (TAR-200) Monotherapy in Patients With Bacillus Calmette-Guérin–Unresponsive Papillary Disease–Only High-Risk Nonmuscle-Invasive Bladder Cancer: 1-Year Disease-Free Survival Results From SUNRISE-1
Presented By: Siamak Daneshmand, MD
|
|
|
|
|
|
|
| SunRISe-1 Trial: Bladder-Sparing Results for BCG-Unresponsive Disease
|
| Felix Guerrero-Ramos, MD, PhD, FEBU
|
|
|
|
|
|
|
|
| BOND-003 Trial: Cretostimogene Grenadenorepvec Shows Promise in BCG-Unresponsive NMIBC
|
| Mark Tyson II, MD, MPH
|
|
|
|
|
|
|
|
| KEYNOTE-905 Study Discussion - Perioperative EV + Pembro in Participants with MIBC Who Are Cisplatin-Ineligible
|
| Jonathan Rosenberg, MD
|
|
|
|
|
|
|
|
| Perioperative Enfortumab Vedotin plus Pembrolizumab in Participants with Muscle-Invasive Bladder Cancer Who Are Cisplatin-Ineligible: The Phase 3 KEYNOTE-905 Study
|
| Christof Vulsteke, MD, PhD
|
|
|
|
|
|
|
|
